Hantz Financial Services’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$602K Sell
21,905
-91
-0.4% -$2.42K 0.01% 656
2026
Q1
$590K Sell
21,996
-1,103
-5% -$33.1K 0.01% 604
2025
Q4
$711K Buy
23,099
+8,446
+58% +$263K 0.01% 542
2025
Q3
$449K Buy
14,653
+9,225
+170% +$225K 0.01% 572
2025
Q2
$112K Buy
5,428
+5,107
+1,591% +$105K ﹤0.01% 733
2025
Q1
$6K Buy
+321
New +$6.73K ﹤0.01% 1106
2020
Q3
Sell
-11
Closed 588
2020
Q2
$0 Buy
+11
New +$300 ﹤0.01% 586

Other funds holding GMAB

Hantz Financial Services's GMAB Position: Q2 2026 in Review

Hantz Financial Services reduced its Genmab (GMAB) stake by 0.41% in Q2 2026, selling an estimated $2.42K and leaving 21,905 shares worth $602K. The position accounts for 0.01% of the portfolio, ranked #656.

Hantz Financial Services first reported a position in GMAB in Q2 2020 and has held it in 7 quarters since. The position peaked at $711K in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Hantz Financial Services held 21,905 shares of Genmab worth $602K as of Q2 2026.
  • Hantz Financial Services sold 91 Genmab shares in Q2 2026, an estimated $2.42K.
  • Genmab made up 0.01% of Hantz Financial Services's portfolio in Q2 2026, its #656 holding.
  • Hantz Financial Services first reported a position in Genmab in Q2 2020 and has held it in 7 quarters since.
  • Hantz Financial Services's Genmab position peaked at $711K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.